Pharmaceuticals
Biopharmaceutical
Development
Commercializing
Rare
Diseases
United
States
M&A Advisory
Lazard
Full Credential Description
Savient Pharmaceuticals, Inc.. United States. Announced Date 11/12/2013. Closed Date 09/01/2014. Deal value: $120m. Advisor to company on sale of substantially all assets to Crealta Pharmaceuticals. Industry: Savient Pharmaceuticals, Inc. was a specialty biopharmaceutical company focused on developing and commercializing treatments for rare diseases.